Novo Nordisk A/S (LON:0TDD)

Market Cap	190.40B -36.0%
Revenue (ttm)	36.88B +16.6%
Net Income	12.13B +9.6%
EPS	2.73 +10.1%
Shares Out	n/a
PE Ratio	15.70
Forward PE	17.16
Dividend	0.94 (1.58%)
Ex-Dividend Date	Aug 18, 2025

Volume	233,707
Average Volume	421,335
Open	59.10
Previous Close	59.32
Day's Range	58.29 - 60.34
52-Week Range	41.45 - 93.80
Beta	0.36
RSI	55.98
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 78,554
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0TDD

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK